ClinicalTrials.Veeva

Menu

FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

S

Sunnybrook Health Sciences Centre

Status

Completed

Conditions

Glioblastoma Multiforme

Treatments

Diagnostic Test: FET-PET/MRI

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.

Enrollment

11 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Each participant must meet all of the following inclusion criteria to participate in this study:

  • ≥ 18 years of age
  • Diagnosis of glioblastoma multiforme
  • Post-maximally safe surgical resection
  • No prior radiation or systemic treatment for high grade glioma
  • Able to tolerate PET/MRI scan with intravenous contrast
  • Willing to provide informed consent

Exclusion criteria

All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study:

  • MRI contraindication
  • Creatinine clearance < 30mL/min
  • Inability to lie still for 60 minutes
  • Gadolinium allergy
  • Positive pregnancy test
  • Breastfeeding
  • Patient unable to follow the protocol for any reason

Trial design

11 participants in 1 patient group

Post-Operative GBM Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
Description:
0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) PET/MRI for planning of radiation therapy of post-operative glioblastoma multiforme patients
Treatment:
Diagnostic Test: FET-PET/MRI

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Jay Detsky, MD; Amit Singnurkar, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems